Share Name Share Symbol Market Type Share ISIN Share Description
Collagen Solutions Plc LSE:COS London Ordinary Share GB00B94T6Y14 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 6.625 30,707 08:00:18
Bid Price Offer Price High Price Low Price Open Price
6.25 7.00 6.625 6.375 6.625
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 4.01 -3.70 -0.76 30
Last Trade Time Trade Type Trade Size Trade Price Currency
08:44:02 O 30,707 6.50 GBX

Collagen Solutions (COS) Latest News (1)

More Collagen Solutions News
Collagen Solutions Takeover Rumours

Collagen Solutions (COS) Discussions and Chat

Collagen Solutions (COS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Collagen Solutions trades in real-time

Collagen Solutions (COS) Top Chat Posts

Collagen Solutions Daily Update: Collagen Solutions Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker COS. The last closing price for Collagen Solutions was 6.63p.
Collagen Solutions Plc has a 4 week average price of 6.30p and a 12 week average price of 2.50p.
The 1 year high share price is 6.63p while the 1 year low share price is currently 0.90p.
There are currently 446,878,910 shares in issue and the average daily traded volume is 125,035 shares. The market capitalisation of Collagen Solutions Plc is £29,605,727.79.
w t tutte: I have had a good think about it and I don't want to sell my shares at 6.5p. I think the shares will fall back if the bid is killed but I still feel the long term outlook for the business is strong. Another factor for me is that if the share price is at 2.5p or 6.5p it only has a smallish impact on my savings.
nxc: Dreams of higher valuations are just that - to ascribe value without the concomitant significant cash injection necessary to achieve that value needs to be taken into account. If the bid fell away you are looking at a sub 2p share price with a probable 1p fundraise.
interstellar: I admire such consistent and patient enthusiasm. I am 60% down on my investment and i'm getting a bit tired of these jam tomorrow announcements and still the share price goes nowhere.
interstellar: I must say the quality of the recent announcements is somewhat poor. Attendance at a confrence, award of a studentship, scientific advisory board????- there are only three things that are important- sales, sales and sales not announcements about house keeping. Next thing we know there will be an annoucemnet about the office cleaning contract. If this is the best they can offer us I am not holding out a lot of hope for an uptick in share price anytime soon
interstellar: JJ- are you trying to ramp this stock. You know it's really very disappointing to get an alert from ADVFN that a new post has been made only to find unsubstantiated twaddle. "Pipeline there and being traversed "- well that is yet to be demonstrated as the company freely admits in its own recent comments- otherwise they would not suffer from delays to revenue flows with its consequent impact on the share value; " its a case of how fast and at what time we get the next news.." -there is no guarantee at this stage or any optimism expressed by the management, that they have successfully filled the sales pipeline with potential contracts; " but could well be probably biggest news ever for the company in my opinion." Admirable enthusiasm but wildly optimistic at this stage. The fact that the share price is a mere 50% of where it was not so long ago testifies to the risks here. The company has a huge senior management team with all its various subsidiaries- very expensive- and , so far, they have shown little sign of delivering what they promised. Don't bet the farm on this one- in fact prepare to lose your shirt! All in my humble opinion
jacobjohn7: He's had his winners I believe also, anyway him buying doesnt make the company. Do your research every one sat waiting for big deals to materialise. The acquisitions of COS have been very astute imo. I agree though the sales targets can slip timescale wise not a biggie, as long as these things gain traction and sales targets are hit, and the pipeline lives up to anywhere near the great promise it upholds. I think the 100m market cap is a good thing to aim for as a medical business, but that in itself puts pressure on the share price.. as it is ambitious, but it is an ambitious company with a good global reach and offering.
interstellar: Well Jaco, BEWARE! it's a ploy David Evans has used before. He and his fellow directors bought a shed load of EKF shares (at around 25pence per) in order to show support for EKF's underlying business. Even at the time fully aware of the poison pill some of that company's acquisitions had proven to be. Today EKF's share price is 8p- 2/3rds of the value lost. IF you dont believe me check out EKF's history over the last year or so. So don't make any judgements about director's purchases- history here has shown it to not necessarily be a wise move or good guide. What will make a difference to COS price is hitting sales targets, getting more contracts in the pipeline so mealy mouthed excuses of 'timing' issues are a thing of the past and they get their fingers out and DELIVER what they promise.
jacobjohn7: Collagen Solutions buys knee implant for ‘bargain’ PERRY GOURLEY Tuesday 15 September 2015 Life sciences firm Collagen Solutions has struck a deal to buy a product used to repair minor damage to knee joints. The acquisition of the assets and intellectual property (IP) for ChondroMimetic is the last in a string of announcements by the Glasgow-based firm as it looks to grow to a £100 million business in the next five years. ChondroMimetic is a collagen-based implant for the treatment of small cartilage and underlying bone defects. The market it is aimed at is estimated to be worth more than $500m (£325m). Collagen Solutions chief executive Stewart White said the deal to buy the product from its owners, Cambridge University spin-out Orthomimetics and Cambridge Enterprise, was an important next step for the company as it was the first acquisition of a medical device. White, pictured, said: “Having established Collagen Solutions as the go to company for providing novel medical grade collagens, we were in a position to look at acquiring products that are collagen related and would give us the opportunity to not only provide part of the product, but to add value. “ChondroMimetic is an ideal first medical device acquisition as it brings us both an established product as well as access to a portfolio of additional IP we can exploit in the future.” The acquisition is being funded through the issue of 869,900 shares – about £100,000 at the current share price – with half of the consideration being paid now and the rest over the next two years. Royalties will also be payable to the vendors on future sales. Analyst Mike Mitchell of house broker Panmure Gordon estimates that the total value of the deal will be “low hundreds of thousands”. He viewed the acquisition as “something of a bargain” given the background to the product. “ChrondroMimetic was Orthomimetics’ key product and investors familiar with this space will recall Belgium-based TiGenix acquiring Orthomimetics in 2009 in a deal valuing the company at €16m (£11.75m),” he pointed out. Mitchell said that any product launch by Collagen Solutions based on the acquisition was some way off as a number of regulatory and manufacturing challenges would need to be navigated. “But we consider the market opportunity to be attractive, playing well with respect to population demographics and increasing demand for effective early interventions which avoid or reduce the need for more expensive treatments in later life.” Ian Harris, director of Orthomimetics, said Collagen Solutions “had the resources and knowledge-base to see ChondroMimetic build on its early promise”. Earlier this month Collagen Solutions said one of its long-term clients had gained US approval for a new device that makes collagen products easier to use. In September it was chosen to take part in a €4m European research project aimed at developing new treatments for Parkinson’s disease. Read more: Follow us: @TheScotsman on Twitter | TheScotsmanNewspaper on Facebook
Collagen Solutions share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Collagen S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200925 14:46:35